ATE551334T1 - Pi3-kinase-hemmer und verfahren zu ihrer verwendung - Google Patents

Pi3-kinase-hemmer und verfahren zu ihrer verwendung

Info

Publication number
ATE551334T1
ATE551334T1 AT08729174T AT08729174T ATE551334T1 AT E551334 T1 ATE551334 T1 AT E551334T1 AT 08729174 T AT08729174 T AT 08729174T AT 08729174 T AT08729174 T AT 08729174T AT E551334 T1 ATE551334 T1 AT E551334T1
Authority
AT
Austria
Prior art keywords
diseases
alone
pharmaceutically acceptable
therapeutic agent
combination
Prior art date
Application number
AT08729174T
Other languages
English (en)
Inventor
Sabina Pecchi
Zhi-Jie Ni
Matthew Burger
Allan Wagman
Gordana Atallah
Sarah Bartulis
Simon Ng
Keith Pfister
Aaron Smith
Yanchen Zhang
Hanne Merritt
Charles Voliva
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE551334T1 publication Critical patent/ATE551334T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT08729174T 2007-02-06 2008-02-06 Pi3-kinase-hemmer und verfahren zu ihrer verwendung ATE551334T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88846507P 2007-02-06 2007-02-06
PCT/US2008/053190 WO2008098058A1 (en) 2007-02-06 2008-02-06 Pi 3-kinase inhibitors and methods of their use

Publications (1)

Publication Number Publication Date
ATE551334T1 true ATE551334T1 (de) 2012-04-15

Family

ID=39485187

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08729174T ATE551334T1 (de) 2007-02-06 2008-02-06 Pi3-kinase-hemmer und verfahren zu ihrer verwendung

Country Status (12)

Country Link
US (1) US8173647B2 (de)
EP (1) EP2118087B1 (de)
JP (1) JP2010518107A (de)
KR (1) KR20090108124A (de)
CN (1) CN101711241A (de)
AT (1) ATE551334T1 (de)
AU (1) AU2008213808B2 (de)
CA (1) CA2675558A1 (de)
EA (1) EA200901065A1 (de)
ES (1) ES2381895T3 (de)
MX (1) MX2009008341A (de)
WO (1) WO2008098058A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TW200908984A (en) * 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
WO2010049481A1 (en) * 2008-10-31 2010-05-06 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US8513242B2 (en) * 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
SG174527A1 (en) 2009-03-27 2011-11-28 Pathway Therapeutics Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
EP2451802A1 (de) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl- und 1,3,5-triazinyl-benzimidazole und ihre verwendung in der krebstherapie
WO2011008931A2 (en) * 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
AU2010338011B2 (en) 2009-12-28 2015-04-02 Development Center For Biotechnology Novel pyrimidine compounds as mTOR and P13K inhibitors
US9315491B2 (en) 2009-12-28 2016-04-19 Development Center For Biotechnology Pyrimidine compounds as mTOR and PI3K inhibitors
JP2013522215A (ja) 2010-03-09 2013-06-13 オーエスアイ・ファーマシューティカルズ，エルエルシー 組合わせ抗癌療法
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
KR20130119928A (ko) 2010-10-01 2013-11-01 노파르티스 아게 피리미딘 유도체의 제조 방법
JP2014500308A (ja) 2010-12-21 2014-01-09 ノバルティス アーゲー Ｖｐｓ３４阻害剤としてのビヘテロアリール化合物
AU2012225382B2 (en) * 2011-03-09 2016-10-27 Celgene Avilomics Research, Inc. PI3 kinase inhibitors and uses thereof
WO2012135160A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
PH12014500682A1 (en) 2011-09-27 2014-05-12 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
PL2794600T3 (pl) * 2011-12-22 2018-06-29 Novartis Ag Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
MX360892B (es) * 2012-05-16 2018-11-20 Novartis Ag Régimen de dosificación para un inhibidor de cinasa pi-3.
MX2014013725A (es) 2012-05-23 2015-02-10 Hoffmann La Roche Composiciones y metodos para obtener y utilizar celulas del endodermo y hepatocitos.
TW201410657A (zh) 2012-08-02 2014-03-16 Endo Pharmaceuticals Inc 經取代胺基－嘧啶衍生物
JP6183053B2 (ja) * 2012-08-22 2017-08-23 宇部興産株式会社 テトラヒドロピラニルピリミジン化合物の製造方法
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CN103012284A (zh) * 2012-12-26 2013-04-03 无锡捷化医药科技有限公司 一种2-氨基-5-溴嘧啶类化合物的制备方法
CN105050602B (zh) * 2013-01-12 2018-05-25 张大为 作为pi3激酶抑制剂的吡啶化合物
GEP201706699B (en) 2013-03-14 2017-07-10 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EA029568B8 (ru) * 2013-05-01 2018-08-31 Ф.Хоффманн-Ля Рош Аг Бигетероарильные соединения и их применения
CN103483345B (zh) * 2013-09-25 2016-07-06 中山大学 Pi3k激酶抑制剂、包含其的药物组合物及其应用
AU2015209133B2 (en) 2014-01-24 2019-10-03 AI Therapeutics, Inc. Apilimod compositions and methods for using same
CN105541792B (zh) * 2014-10-22 2018-03-13 山东轩竹医药科技有限公司 多环类pi3k抑制剂
HUE044557T2 (hu) 2014-11-07 2019-11-28 Ai Therapeutics Inc Apilimod, veserák kezelésében történõ alkalmazásra
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
CN105294572A (zh) * 2015-10-13 2016-02-03 安徽泓德化工技术有限公司 一甲氧基嘧啶胺的制备方法
RU2018140001A (ru) * 2016-05-18 2020-06-18 Пикур Терапьютикс Аг Лечение повреждений кожи
DK3458067T3 (da) * 2016-05-18 2021-04-06 Univ Basel Behandling af neurologiske lidelser
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
WO2018136917A1 (en) 2017-01-23 2018-07-26 Cadent Therapeutics, Inc. Potassium channel modulators
KR20240097982A (ko) 2017-05-23 2024-06-27 메이 파마, 아이엔씨. 병용 요법
MA49921A (fr) 2017-08-14 2021-05-12 Mei Pharma Inc Polythérapie
CN109651341A (zh) * 2017-10-11 2019-04-19 上海医药工业研究院 二吗啉氰基嘧(吡)啶类衍生物及作为抗肿瘤药物应用
MX2020005024A (es) 2017-11-23 2020-08-13 Piqur Therapeutics Ag Tratamiento de trastornos de la piel.
CA3085460A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
AU2019251360B2 (en) * 2018-04-10 2025-03-13 Neuropore Therapies, Inc. Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways
EP3870291A1 (de) 2018-10-22 2021-09-01 Cadent Therapeutics, Inc. Kristalline formen von kaliumkanalmodulatoren
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN114213340B (zh) 2022-02-22 2022-06-07 北京蓝晶微生物科技有限公司 2,4-二氨基嘧啶氧化物的制备方法
CN116496223A (zh) * 2023-04-26 2023-07-28 福建凯昕药业有限公司 5-溴-4-甲基-2-三氟甲基嘧啶的一种制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT340933B (de) * 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
US4929726A (en) * 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
GB9012311D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
CA2190973C (en) * 1995-04-13 2001-06-19 Yasuo Konno Novel 4,6-diarylpyrimidine derivatives and salts thereof
JP3734907B2 (ja) * 1996-12-19 2006-01-11 富士写真フイルム株式会社 現像処理方法
US6251900B1 (en) * 1997-07-24 2001-06-26 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compounds and antitumor agent containing the same as active ingredient
US6150362A (en) * 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
SI0930302T1 (en) * 1998-01-16 2003-10-31 F. Hoffmann-La Roche Ag Benzosulfone derivatives
CA2359680A1 (en) 1999-01-22 2000-07-27 David M. Armistead Kinase inhibitors
US6495558B1 (en) * 1999-01-22 2002-12-17 Amgen Inc. Kinase inhibitors
WO2001072745A1 (en) 2000-03-29 2001-10-04 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders
CN100345830C (zh) 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物
WO2001083460A1 (en) 2000-04-28 2001-11-08 Tanabe Seiyaku Co., Ltd. Cyclic compounds
CA2409762A1 (en) * 2000-06-23 2002-01-03 Donald J.P. Pinto Heteroaryl-phenyl substituted factor xa inhibitors
AP2003002762A0 (en) 2000-09-15 2003-03-31 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
SE0004053D0 (sv) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
AU2002255452B2 (en) 2000-12-21 2006-06-08 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1395561A1 (de) * 2001-05-25 2004-03-10 Boehringer Ingelheim Pharmaceuticals Inc. Carbamat und oxamid verbindungen als inhibitoren der cytokinproduktion
JP2005500294A (ja) 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
US6603000B2 (en) * 2001-07-11 2003-08-05 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis for heteroarylamine compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003078427A1 (en) * 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) * 2002-03-15 2003-09-29 Binch, Hayley Compositions useful as inhibitors of protein kinases
WO2003078426A1 (en) * 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazine as inhibitors of protein kinases
US7091343B2 (en) * 2002-03-15 2006-08-15 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AU2003295776B2 (en) * 2002-11-21 2011-05-12 Novartis Vaccines And Diagnostics, Inc. 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
CA2519677A1 (en) 2003-03-24 2004-10-07 Merck & Co., Inc. Biaryl substituted 6-membered heterocycles as sodium channel blockers
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
EP1651619A1 (de) 2003-07-15 2006-05-03 Neurogen Corporation Substituierte pyrimidin-4-ylaminanaloge als vanilloidrezeptorliganden
CA2531619A1 (en) 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
GB0415364D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415365D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
EP1979325A1 (de) * 2006-01-11 2008-10-15 AstraZeneca AB Morpholinopyrimidinderivate und ihre verwendung in der therapie
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2008023159A1 (en) * 2006-08-24 2008-02-28 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders

Also Published As

Publication number Publication date
EP2118087A1 (de) 2009-11-18
ES2381895T3 (es) 2012-06-01
WO2008098058A1 (en) 2008-08-14
CA2675558A1 (en) 2008-08-14
EA200901065A1 (ru) 2010-02-26
MX2009008341A (es) 2009-08-12
EP2118087B1 (de) 2012-03-28
AU2008213808B2 (en) 2011-11-10
AU2008213808A8 (en) 2009-09-24
US20100048547A1 (en) 2010-02-25
AU2008213808A1 (en) 2008-08-14
CN101711241A (zh) 2010-05-19
JP2010518107A (ja) 2010-05-27
KR20090108124A (ko) 2009-10-14
US8173647B2 (en) 2012-05-08

Similar Documents

Publication Publication Date Title
ATE551334T1 (de) Pi3-kinase-hemmer und verfahren zu ihrer verwendung
MX2010000716A (es) Compuestos de heteroarilo biciclicos y su uso como inhibidores de cinasa.
JO2660B1 (en) Pi-3 inhibitors and methods of use
MX2008010397A (es) Inhibidores de pi-3 quinasa y metodos para su uso.
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
CY1118513T1 (el) Αναστολεις πρωτεϊνικης κινασης (παραλλαγες), χρηση αυτων στη θεραπεια ογκολογικων νοσων και μια φαρμακευτικη συνθεση βασισμενη σε αυτους
WO2009155527A3 (en) Phosphatidylinositol 3 kinase inhibitors
JO3002B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
WO2012068106A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
MY170656A (en) Kinase inhibitors
WO2012068096A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012135697A3 (en) Novel rho kinase inhibitors and methods of use
MX2010007584A (es) Inhibidores de proteina cinasa y uso de los mismos.
PA8821301A1 (es) Inhibidores a base de hidroxamato de desacetilasas b
IL219644A0 (en) Kinase inhibitors and methods of use thereof
PH12015501836A1 (en) 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors
WO2012119006A3 (en) Derivatives of pyrazole-substituted amino-heteroaryl compounds
TNSN08531A1 (en) Phenylacetic acid derivatives as cox - 2 inhibitors
SE0402591D0 (sv) Novel use
TR201901937T4 (tr) 8-metil-1-fenil-imidazol[1,5-a]pirazin bileşikleri.
GEP201706680B (en) Catechol o-methyltransferase activity inhibiting compounds